Hangzhou Tigermed Consulting Co Ltd
300347
Company Profile
Business description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's offered services include bioanalytical, medical writing, biostatistical analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Contact
Block 8, No. 19 Jugong Road
Room 2001-2010, 20th Floor
Xixing Sub-District, Binjiang District
Hangzhou310053
CHNT: +86 57128887227
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
10,185
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
stocks
Nvidia: Back in business in China; Raising fair value estimate
Nvidia is poised to become more dominant than ever as it is allowed to sell its key H20 GPUs in China.
stocks
Our top ASX picks in every sector
These companies are our top choices for investors wanting to boost Aussie exposure.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,816.40 | 58.90 | -0.66% |
CAC 40 | 7,722.09 | 44.12 | -0.57% |
DAX 40 | 24,009.38 | 50.91 | -0.21% |
Dow JONES (US) | 44,144.66 | 121.37 | 0.28% |
FTSE 100 | 8,926.55 | 11.77 | -0.13% |
HKSE | 24,517.76 | 72.36 | -0.29% |
NASDAQ | 20,696.19 | 18.39 | 0.09% |
Nikkei 225 | 39,663.40 | 14.62 | -0.04% |
NZX 50 Index | 12,754.59 | 64.96 | 0.51% |
S&P 500 | 6,253.08 | 9.32 | 0.15% |
S&P/ASX 200 | 8,561.80 | 68.50 | -0.79% |
SSE Composite Index | 3,503.78 | 1.22 | -0.03% |